Non-mammalian animal models of Parkinson's disease for drug discovery

Expert Opinion on Drug Discovery

Volumn 5, Issue 2, 2010, Pages 165-176

  Lim, Kah Leong ^a,b,c  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Caenorhabditis elegans; Drosophila; LRRK2; Neurodegeneration; Parkin; Parkinsons disease; Synuclein

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; ANTIOXIDANT; APOMORPHINE; BROMOCRIPTINE; CELASTROL; DEXTROMETHORPHAN; DJ 1 PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; GELDANAMYCIN; LEUCINE RICH REPEAT KINASE 2; LISURIDE; MINOCYCLINE; PARKIN; QUINPIROLE; RAPAMYCIN; UBIDECARENONE;

CAENORHABDITIS ELEGANS; DISEASE MODEL; DROSOPHILA; GENE FUNCTION; GENE INTERACTION; GENETIC MODEL; HUMAN; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 75449106779     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903527675     Document Type: Review

References (70)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-386
2. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71(7):474-480
3. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211
4. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368-376
5. Alexander GE. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci 2004;6:259-280
6. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16(2):R183-94
7. Tan JM, Wong ES, Lim KL. Protein misfolding and aggregation in Parkinson disease. Antioxid Redox Signal 2009;11(9):2119-2134
8. Lim KL, Ng CH. Genetic models of Parkinson disease. Biochim Biophys Acta 2009;1792(7):604-615
9. Lu B, Vogel H. Drosophila models of neurodegenerative diseases. Annu Rev Pathol 2009;4:315-342
10. Chesselet MF, Fleming S, Mortazavi F, Meurers B. Strengths and limitations of genetic mouse models of Parkinson's disease. Parkinsonism Relat Disord 2008;14(Suppl 2):S84-7
11. Muqit MM, Feany MB. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat Rev Neurosci 2002;3(3):237-243
12. Lakso M, Vartiainen S, Moilanen AM, et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 2003;86(1):165-172
13. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science 1998;282(5396):2028-2033
14. McDonald PW, Jessen T, Field JR, Blakely RD. Dopamine signaling architecture in Caenorhabditis elegans. Cell Mol Neurobiol 2006;26(4-6):593-618
15. Nass R, Hall DH, Miller DM III, Blakely RD. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc Natl Acad Sci USA 2002;99(5):3264-3269
16. Nass R, Miller DM, Blakely RD. C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat Disord 2001;7(3):185-191
17. Kuwahara T, Koyama A, Gengyo-Ando K, et al. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J Biol Chem 2006;281(1):334-340
18. van Ham TJ, Thijssen KL, Breitling R, et al. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet 2008;4(3):e1000027
19. Springer W, Hoppe T, Schmidt E, Baumeister R. A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum Mol Genet 2005;14(22):3407-3423
20. Lo Bianco C, Schneider BL, Bauer M, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci USA 2004;101(50):17510-17515
21. Petrucelli L, O'Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002;36(6):1007-1019
22. Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther 2005;16(2):262-270
23. Ved R, Saha S, Westlund B, et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 2005;280(52):42655-42668
24. Saha S, Guillily MD, Ferree A, et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009;29(29):9210-9218
25. Wolozin B, Saha S, Guillily M, et al. Investigating convergent actions of genes linked to familial Parkinson's disease. Neurodegener Dis 2008;5(3-4):182-185
26. Samann J, Hegermann J, von Gromoff E, et al. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem 2009;284(24):16482-16491
27. Nass R, Merchant KM, Ryan T. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need. Mol Interv 2008 8(6):284-293
28. Kuwahara T, Koyama A, Koyama S, et al. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in {alpha}-synuclein transgenic C. elegans. Hum Mol Genet 2008;17(19):2997-3009
29. Hamamichi S, Rivas RN, Knight AL, et al. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci USA 2008;105(2):728-733
30. Nass R, Hahn MK, Jessen T, et al. A genetic screen in Caenorhabditis elegans for dopamine neuron insensitivity to 6-hydroxydopamine identifies dopamine transporter mutants impacting transporter biosynthesis and trafficking. J Neurochem 2005;94(3):774-785
31. Cao S, Gelwix CC, Caldwell KA, Caldwell GA. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 2005;25(15):3801-3812
32. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219(4587):979-980
33. Braungart E, Gerlach M, Riederer P, et al. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis 2004;1(4-5):175-183
34. Locke CJ, Fox SA, Caldwell GA, Caldwell KA. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. Neurosci Lett 2008;439(2):129-133
35. Zhang W, Shin EJ, Wang T, et al. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J 2006;20(14):2496-2511
36. Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002;58(4 Suppl 1):S9-18
37. Kritzer JA, Hamamichi S, McCaffery JM, et al. Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol 2009;5(9):655-663
38. Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004;24(48):10993- 10998
39. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404(6776):394-398
40. Whitworth AJ, Theodore DA, Greene JC, et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci USA 2005;102(22):8024-8029
41. Wang C, Lu R, Ouyang X, et al. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J Neurosci 2007;27(32):8563-8570
42. Greene JC, Whitworth AJ, Kuo I, et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 2003;100(7):4078-4083
43. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006;441(7097):1162-1166
44. Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006;441(7097):1157-1161
45. Yang Y, Gehrke S, Imai Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 2006;103(28):10793-10798
46. Meulener M, Whitworth AJ, Armstrong-Gold CE, et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol 2005;15(17):1572-1577
47. Menzies FM, Yenisetti SC, Min KT. Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr Biol 2005;15(17):1578-1582
48. Park J, Kim SY, Cha GH, et al. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 2005;361:133-139
49. Yang Y, Gehrke S, Haque ME, et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 2005;102(38):13670-13675
50. Lavara-Culebras E, Paricio N. Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. Gene 2007;400(1-2):158-165
51. Meulener MC, Xu K, Thomson L, et al. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci USA 2006;103(33):12517-12522
52. Imai Y, Gehrke S, Wang HQ, et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008;27(18):2432-2443
53. Liu Z, Wang X, Yu Y, et al. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci USA 2008;105(7):2693-2698
54. Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009;29(36):11257-11262
55. Venderova K, Kabbach G, Abdel-Messih E, et al. Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum Mol Genet 2009;18(22):4390-4404
56. Greene JC, Whitworth AJ, Andrews LA, et al. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 2005;14(6):799-811
57. Auluck PK, Chan HY, Trojanowski JQ, et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002;295(5556):865-868
58. Klucken J, Shin Y, Masliah E, et al. Hsp70 Reduces alpha-synuclein aggregation and toxicity. J Biol Chem 2004;279(24):25497-25502
59. Poole AC, Thomas RE, Andrews LA, et al. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 2008;105(5):1638-1643
60. Deng H, Dodson MW, Huang H, Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/ or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 2008;105(38):14503-14508
61. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008;105(32):11364-11369
62. Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 2002;8(11):1185-1186
63. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 2005;280(4):2873-2878
64. Wang D, Qian L, Xiong H, et al. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci USA 2006;103(36):13520- 13525
65. Tain LS, Mortiboys H, Tao RN, et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 2009;12(9):1129-1135
66. Faust K, Gehrke S, Yang Y, et al. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci 2009;10:109
67. Rohde CB, Zeng F, Gonzalez-Rubio R, et al. Microfluidic system for on-chip high-throughput whole-animal sorting and screening at subcellular resolution. Proc Natl Acad Sci USA 2007;104(35):13891-13895
68. Zeng F, Rohde CB, Yanik MF. Sub-cellular precision on-chip small-animal immobilization, multi-photon imaging and femtosecond-laser manipulation. Lab Chip 2008;8(5):653-656
69. Brokars J. Fly fishing on the brain. Biol-IT World 2002;June. Available from: www. bio-itworld.com/archive/061202/fishing. html
70. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413(6857):739-743